Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home
Open Access
- 25 April 2016
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 18 (7), 671-677
- https://doi.org/10.1111/dom.12663
Abstract
To assess the performance and safety of an integrated bihormonal artificial pancreas system consisting of one wearable device and two wireless glucose sensor transmitters during short‐term daily use at home. Adult patients with type 1 diabetes using an insulin pump were invited to enrol in this randomized crossover study. Treatment with the artificial pancreas started with a day and night in the clinical research centre, followed by 3 days at home. The control period consisted of 4 days of insulin pump therapy at home with blinded continuous glucose monitoring for data collection. Days 2–4 were predefined as the analysis period, with median glucose as the primary outcome. A total of 10 patients completed the study. The median [interquartile range (IQR)] glucose level was similar for the two treatments [7.3 (7.0–7.6) mmol/l for the artificial pancreas vs. 7.7 (7.0–9.0) mmol/l for the control; p = 0.123]. The median (IQR) percentage of time spent in euglycaemia (3.9–10 mmol/l) was longer during use of the artificial pancreas [84.7 (82.2–87.8)% for the artificial pancreas vs. 68.5 (57.9–83.6)% for the control; p = 0.007]. Time in hypoglycaemia was 1.3 (0.2–3.2)% for the artificial pancreas and 2.4 (0.4–10.3)% for the control treatment (p = 0.139). Separate analysis of daytime and night‐time showed that the improvements were mainly achieved during the night. The results of this pilot study suggest that our integrated artificial pancreas provides better glucose control than insulin pump therapy in patients with type 1 diabetes at home and that the treatment is safe.Keywords
Funding Information
- European Commission under the Seventh Framework Program (PCDIAB) (305654)
This publication has 18 references indexed in Scilit:
- Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trialThe Lancet Diabetes & Endocrinology, 2016
- 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trialThe Lancet Diabetes & Endocrinology, 2015
- Pharmacokinetics and pharmacodynamics of various glucagon dosages at different blood glucose levelsDiabetes, Obesity and Metabolism, 2015
- Day and Night Closed-Loop Control Using the Integrated Medtronic Hybrid Closed-Loop System in Type 1 Diabetes at Diabetes CampDiabetes Care, 2015
- Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trialThe Lancet Diabetes & Endocrinology, 2014
- Outpatient Glycemic Control with a Bionic Pancreas in Type 1 DiabetesThe New England Journal of Medicine, 2014
- Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover studyThe Lancet Diabetes & Endocrinology, 2014
- Feasibility of a Portable Bihormonal Closed-Loop System to Control Glucose Excursions at Home Under Free-Living Conditions for 48 HoursDiabetes Technology & Therapeutics, 2014
- Statistical Tools to Analyze Continuous Glucose Monitor DataDiabetes Technology & Therapeutics, 2009
- The Dawn Phenomenon Revisited: Implications for Diabetes TherapyEndocrine Practice, 2005